Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

Vaccine

Volumn 26, Issue 8, 2008, Pages 1072-1082

  Mettens, Pascal ^a   Dubois, Patrice M ^a   Demoitié, Marie Ange ^a   Bayat, Babak ^a   Donner, Marie Noëlle ^a   Bourguignon, Patricia ^a   Stewart, V Ann ^b   Heppner Jr , D Gray ^b   Garçon, Nathalie ^a   Cohen, Joe ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Adjuvant; AS01B; AS02A; Immune response; Malaria; RTS,S

Indexed keywords

ADJUVANT; AS 01B; AS 02A; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; RTS,S VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IN VIVO STUDY; INFECTION PREVENTION; MONKEY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTOZOAL INFECTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; INTERFERON TYPE II; INTERLEUKIN-2; MACACA MULATTA; MALARIA VACCINES; MICE; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39149099786     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.018     Document Type: Article

References (66)

1. Nussenzweig R.S., Vanderberg J., Most H., and Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216 111 (1967) 160-162
2. Nussenzweig R.S., Vanderberg J.P., Most H., and Orton C. Specificity of protective immunity produced by X-irradiated Plasmodium berghei sporozoites. Nature 222 192 (1969) 488-489
3. Clyde D.F., Most H., McCarthy V.C., and Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 266 3 (1973) 169-177
4. Rieckmann K.H., Carson P.E., Beaudoin R.L., Cassells J.S., and Sell K.W. Sporozoite-induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans Roy Soc Trop Med Hyg 68 3 (1974) 258-259
5. Potocnjak P., Yoshida N., Nussenzweig R.S., and Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 151 6 (1980) 1504-1513
6. Hollingdale M.R., Zavala F., Nussenzweig R.S., and Nussenzweig V. Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells. J Immunol 128 4 (1982) 1929-1930
7. + cytolytic T cell clone confers protection against murine malaria. J Exp Med 172 5 (1990) 1353-1357
8. + cells and malaria sporozoites. Immunol Lett 25 1-3 (1990) 59-64
9. + T cell clones against Plasmodium yoelii liver stages. J Immunol 150 4 (1993) 1471-1478
10. + T cells in immunity to malaria sporozoites. J Immunol 151 5 (1993) 2690-2698
11. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., and Nussenzweig V. γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330 6149 (1987) 664-666
12. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85 2 (1988) 573-576
13. + T cell- and IFN-γ-dependent elimination of infected hepatocytes. J Immunol 157 9 (1996) 4061-4067
14. + T cells. J Exp Med 180 1 (1994) 353-358
15. Tsuji M., Miyahira Y., Nussenzweig R.S., Aguet M., Reichel M., and Zavala F. Development of anti-malaria immunity in mice lacking IFN-γ receptor. J Immunol 154 10 (1995) 5338-5344
16. Weiss W.R., Mellouk S., Houghten R.A., Sedegah M., Kumar S., Good M.F., et al. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med 171 3 (1990) 763-773
17. + cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture. Infect Immun 68 6 (2000) 3403-3411
18. + T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 22 3 (2000) 157-160
19. Zavala F., Cochrane A.H., Nardin E.H., Nussenzweig R.S., and Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med 157 6 (1983) 1947-1957
20. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., and Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341 6240 (1989) 323-326
21. Franke E.D., Corradin G., and Hoffman S.L. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. J Immunol 159 7 (1997) 3424-3433
22. Meraldi V., Audran R., Romero J.F., Brossard V., Bauer J., López J.A., et al. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 21 19-20 (2003) 2485-2491
23. Sedegah M., Hedstrom R., Hobart P., and Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 91 21 (1994) 9866-9870
24. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 4 (1998) 397-402
25. Dégano P., Schneider J., Hannan C.M., Gilbert S.C., and Hill A.V.S. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18 7-8 (1999) 623-632
26. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 336 2 (1997) 86-91
27. Bojang K.A., Milligan P.J.M., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 9297 (2001) 1927-1934
28. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 4 (2001) 640-647
29. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 9443 (2004) 1411-1420
30. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178 4 (1998) 1139-1144
31. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180 5 (1999) 1656-1664
32. Pinder M., Reece W.H.H., Plebanski M., Akinwunmi P., Flanagan K.L., Lee E.A.M., et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in the Gambia. Clin Exp Immunol 135 2 (2004) 286-293
33. + T cells producing IFN-γ. J Immunol 171 12 (2003) 6961-6967
34. Garçon N., Heppner D.G., and Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2 2 (2003) 231-238
35. ACH320. Vaccine 18 13 (2000) 1166-1177
36. Walzer T., Joubert G., Dubois P.M., Tomkowiak M., Arpin C., Pihlgren M., et al. Characterization at the single-cell level of naive and primed CD8 T cell cytokine responses. Cell Immunol 206 1 (2000) 16-25
37. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 255 1-2 (2001) 27-40
38. + T cell responses in rhesus macaques. J Immunol Methods 288 1-2 (2004) 61-79
39. Stewart V.A., McGrath S.M., Davis S., Hess A.S., Ware L.A., Kester K.E., et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24 42-43 (2006) 6483-6492
40. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner Jr. D.G., Hall T., et al. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine 25 29 (2007) 5359-5366
41. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., and Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529. Expert Rev Vaccines 2 2 (2003) 219-229
42. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 2 (2002) 926-932
43. Austyn J.M., Steinman R.M., Weinstein D.E., Granelli-Piperno A., and Palladino M.A. Dendritic cells initiate a two-stage mechanism for T lymphocyte proliferation. J Exp Med 157 4 (1983) 1101-1115
44. Van Voorhis W.C., Valinsky J., Hoffman E., Luban J., Hair L.S., and Steinman R.M. Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 158 1 (1983) 174-191
45. + T cells. J Immunol 154 10 (1995) 5071-5079
46. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 314 6011 (1985) 537-539
47. Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S., et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72 2 (1993) 291-300
48. Braley-Mullen H. Antigen requirements for induction of B-memory cells: studies with dinitrophenyl coupled to T-dependent and T-independent carriers. J Exp Med 147 6 (1978) 1824-1831
49. - T4 cell subsets. J Immunol 142 8 (1989) 2597-2607
50. Wu J.-Y., Gardner B.H., Murphy C.I., Seals J.R., Kensil C.R., Recchia J., et al. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol 148 5 (1992) 1519-1525
51. Ma J., Bulger P.A., Dante S., Davis D.R., Perilli-Palmer B., and Coughlin R.T. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes. J Infect Dis 171 4 (1995) 909-915
52. Kashala O., Amador R., Valero M.V., Moreno A., Barbosa A., Nickel B., et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 20 17-18 (2002) 2263-2277
53. Carbone F.R., Kurts C., Bennett S.R.M., Miller J.F.A.P., and Heath W.R. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 19 8 (1998) 368-373
54. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137
55. Nussler A., Pied S., Goma J., Rénia L., Miltgen F., Grau G.E., et al. TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. Int Immunol 3 4 (1991) 317-321
56. Heller R.A., Song K., Fan N., and Chang D.J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70 1 (1992) 47-56
57. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino Jr. M.A., and Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 88 20 (1991) 9292-9296
58. + cytotoxic T lymphocyte-mediated lysis. J Immunol 150 10 (1993) 4303-4314
59. Shiver J.W., Fu T.-M., Chen L., Casimiro D.R., Davies M.-E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
60. Allen T.M., Vogel T.U., Fuller D.H., Mothé B.R., Steffen S., Boyson J.E., et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164 9 (2000) 4968-4978
61. Sallusto F., Lenig D., Förster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 6754 (1999) 708-712
62. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune responses to human papilloma virus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 188 2 (2003) 327-338
63. Yan M., Peng J., Jabbar I.A., Liu X., Filgueira L., Frazer I.H., et al. Activation of dendritic cells by human papilloma virus-like particles through TLR4 and NF-κB-mediated signalling, moderated by TGF-β. Immunol Cell Biol 83 1 (2005) 83-91
64. Stewart V.A., Walsh D.S., McGrath S.M., Kester K.E., Cummings J.F., Voss G., et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine 24 42-43 (2006) 6493-6502
65. Bruna-Romero O., Gonzalez-Aseguinolaza G., Hafalla J.C., Tsuji M., and Nussenzweig R.S. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 98 20 (2001) 11491-11496
66. Stewart V.A., McGrath S.M., Dubois P.M., Pau M.G., Mettens P., Shott J., et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75 5 (2007) 2283-2290